Status:
COMPLETED
Extension Study to VEG105192 to Assess Pazopanib in Patients With Advanced/Metastatic Renal Cell Cancer
Lead Sponsor:
GlaxoSmithKline
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is an open-label, international, multi-center study designed to provide access to pazopanib for subjects who have been enrolled in the Phase III renal cell carcinoma study (VEG105192) and have pr...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Progressed from VEG105192 study treatment
- Patient's VEG105192 was placebo
- Baseline has good organ function
- Exclusion criteria:
- No brain metastasis
Exclusion
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00387764
Start Date
September 1 2006
End Date
October 1 2012
Last Update
January 14 2014
Active Locations (58)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Capital Federal, Buenos Aires, Argentina, C1405CUB
2
GSK Investigational Site
Córdoba, Córdoba Province, Argentina, 5000
3
GSK Investigational Site
Rosario, Santa Fe Province, Argentina, S2000KZE
4
GSK Investigational Site
Quilmes, Argentina, 1878